Oyster Point Pharma Inc logo

OYST - Oyster Point Pharma Inc News Story

$20.45 -0.9  -4.2%

Last Trade - 16/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £383.1m
Enterprise Value £243.9m
Revenue £n/a
Position in Universe 3450th / 6850

BRIEF-Oyster Point Pharma Announces FDA Acceptance For Filing New Drug Application For OC-01 Nasal Spray For Treatment Of Signs And Symptoms Of Dry Eye Disease

Tue 2nd March, 2021 11:34am
March 2 (Reuters) - Oyster Point Pharma Inc  OYST.O :
    * OYSTER POINT PHARMA ANNOUNCES FDA ACCEPTANCE FOR FILING
NEW DRUG
APPLICATION FOR OC-01 (VARENICLINE) NASAL SPRAY FOR THE
TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE
    * OYSTER POINT PHARMA INC - PRESCRIPTION DRUG USER FEE ACT
(PDUFA)
TARGET ACTION DATE IS OCTOBER 17, 2021
    * OYSTER POINT PHARMA INC - U.S. FDA HAS STATED THAT IT DOES
NOT
INTEND TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS NASAL
SPRAY APPLICATION
    * OYSTER POINT PHARMA INC - PLANNED U.S. LAUNCH OF OC-01
(VARENICLINE) NASAL SPRAY IN Q4 OF 2021, IF APPROVED BY FDA

Source text for Eikon:  ID:nGNX8S4sBB 
Further company coverage:  OYST.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.